CD44 and breast carcinoma: To investigate the CD44-targeted delivery of the TPL/NPs, the CD44-positve MDA-MB-231 breast cancer cell line and CD44-negative MCF-7 epithelial cell line were chosen (Additional file 1: Fig. S8) [27].